BIOPRODUCTION CONGRESS DUBLIN 2017

Integrating disposable tech? Size matters, says BMS

By Flora Southey

- Last updated on GMT

GettyImages/Gam1983
GettyImages/Gam1983

Related tags Disposable Bristol-myers squibb Stainless steel

Size can be a restricting factor when introducing single-use technologies into a pre-existing facility according to BMS, which hopes to integrate disposable equipment at a US-based site.

As the single-use trend continues and biomanufacturers integrate disposable bioreactors into new and existing facilities, Bristol-Myers Squibb said firms should consider equipment and plant size to avoid disruptions to operations.

“It’s not always easy to integrate a 2,000L disposable bioreactor into an area that’s already maxed out, so that what was meant to be a straight forward introduction into disposables become complicated,” ​said BMS’ Mairead Looby at last week’s BioProduction Congress in Dublin, Ireland.

“You would end up having to knock down walls, move out equipment you wouldn’t necessarily want to move out,” ​she added.

However, when increasing scale at an existing site – to 2,000L or up to 5,000L – Looby said there is more room to introduce disposable equipment, such as single-use mixers, medium buffer bags, connectors, valves and piping.

Single-use from the outset

Looby advised biopharmaceutical firms to implement disposable technologies from the beginning.

“When you’re starting off from scratch, you shouldn’t even really consider fixed equipment,” ​she said.

“If your cells can handle disposables – and you need to check that – there shouldn’t be a debate…the evaluation has been done, with significant benefit shown for disposables,” ​she added, citing decreased contamination risk.

BMS moves to single-use

According to Looby, an older BMS site in the US – the firm did not disclose its exact location – is looking to integrate single-use technologies.

“We have very limited single-use components in the process ​[at this site], we have fixed stainless-steel tanks and connections…it’s fairly rigid,” ​she said.

“In this facility, there is a lot of fixed piping, stainless steel rigid piping, we’d look to introduce much more flexible connections in the future. There is huge opportunity within that facility for us to introduce single-use,” ​she added.

Looby said the firm plans to replace the 5,000 stainless steel bioreactor with two 2,000L single-use bioreactors, and potentially reduce that in the future.

"With that particular process, we are looking to take it to the next level, and move it up from a 2g per litre process to a 5g per litre process, so instead of having 2 x 2,000L single-use bioreactors in the future, that would move to 1 2,000L single-use bioreactor,” ​she said.

Related news

Show more

Related products

Trends in Biopharmaceutical Raw Material Selection

Trends in Biopharmaceutical Raw Material Selection

Actylis – The Partner of Choice | 31-Jan-2023 | Business Advice

Join us as our in-house experts, along with Cecile Bellamy from Pfizer, discuss current and future trends in biopharmaceutical raw material selection.

Liposomal and Nanoparticle Technology

Liposomal and Nanoparticle Technology

Pfizer CentreOne | 18-Nov-2022 | Technical / White Paper

Medical science is continuously searching for better ways to administer drugs into the body and to maximize the therapeutic effectiveness of the drugs...

Discover the world of upstream bioprocessing

Discover the world of upstream bioprocessing

Eppendorf Bioprocess Solutions | 07-Sep-2022 | Technical / White Paper

A must-read for all bioprocess scientists: This bundle of four ebooks created by Eppendorf guides you through the world of upstream bioprocessing.

The Reagents Behind Much of Molecular Biology

The Reagents Behind Much of Molecular Biology

Thermo Fisher Scientific | 25-Jul-2022 | Case Study

The ability to amplify, modify and fabricate DNA is fundamental to modern molecular biology. Why do so many researchers take their constituent parts for...

Related suppliers

Follow us

Products

View more

Webinars